2022
Tracking Emergence of New Motor and Non-Motor Symptoms Using the MDS-UPDRS: A Novel Outcome Measure for Early Parkinson’s Disease?
Tosin M, Simuni T, Stebbins G, Cedarbaum J. Tracking Emergence of New Motor and Non-Motor Symptoms Using the MDS-UPDRS: A Novel Outcome Measure for Early Parkinson’s Disease? Journal Of Parkinson's Disease 2022, 12: 1345-1351. PMID: 35466955, PMCID: PMC9198734, DOI: 10.3233/jpd-223170.Peer-Reviewed Original ResearchConceptsEmergent symptomsDisease progressionOutcome measuresParkinson's disease clinical trialsNon-motor symptomsEarly Parkinson's diseaseDaily Living ScalePatient-reported experiencesClinical rating scalesNovel outcome measuresSymptomatic treatmentPD progressionClinical trialsMedian numberDaily livingLiving ScaleParkinson's diseaseSummary scoresMDS-UPDRSUseful markerRating ScaleSTX groupProgressionStxSymptoms
1991
Effect of MK-458 (HPMC) in Parkinson's Disease Previously Untreated With Dopaminergic Drugs. A Double-Blind, Placebo-Controlled Multicenter Study.
Koller WC, Block GA, Ahlskog JE, Ahrens S, Cedarbaum JM, Cyhan G, Goetz CG, LeWitt PA, Liss C, McLean L, Moses H, Muenter M, Nausieda P, Sanchez-Ramos J, Reich S, Singer C, Stellar S, Weiner W. Effect of MK-458 (HPMC) in Parkinson's Disease Previously Untreated With Dopaminergic Drugs. A Double-Blind, Placebo-Controlled Multicenter Study. Clinical Neuropharmacology 1991, 14: 322. PMID: 1913699, DOI: 10.1097/00002826-199108000-00004.Peer-Reviewed Original ResearchConceptsMK-458Early Parkinson's diseaseParkinson's diseaseDopaminergic drugsDisability Rating ScoreDopamine receptor agonismPlacebo-controlled evaluationPatient global assessmentClinical rating scalesParkinsonian symptomsAntiparkinsonian efficacyMulticenter studyAdverse reactionsIdeal treatmentReceptor agonistReceptor agonismSustained release formulationPlaceboGlobal assessmentDiseaseRating ScaleSignificant decreaseDrugsPatientsRating scores